1245079-21-3

Upstream product

• 915100-66-2 (E)-1,2,4-trifluoro-5-(2-nitrovinyl)benzene 
• 956924-25-7 2-nitro-1-(2,4,5-trifluorophenyl)ethanol 
• 165047-24-5 2,4,5-trifluorobenzaldehyde 
• 951127-26-7 1-(2,5-difluorophenyl)-2-nitroethanol 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 2646-90-4 2,5-difluorobenzaldehyde 

Downstream Products

• 1245079-22-4 [(3R,4S)-4-(2,5-difluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1376609-81-2 2-[(3R,4S)-3-tert-butoxycarbonylamino-4-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrimidine-5-carboxylic acid methyl ester 
• 1376609-82-3 2-[(3R,4S)-3-tert-butoxycarbonylamino-4-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrimidine-5-carboxylic acid 
• 1376609-96-9 [(3R,4S)-4-(2,5-difluorophenyl)-1-(5-{[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl](methyl)carbamoyl}pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1376609-97-0 {(3R,4S)-4-(2,5-difluorophenyl)-1-[5-({1-[3-(1-fluoro-1-methylethyl)[1,2,4]oxadiazol-5-yl]piperidin-4-yl}(methyl)carbamoyl)pyrimidin-2-yl]pyrrolidin-3-yl}carbamic acid tert-butyl ester 
• 1376610-75-1 {(3R,4S)-1-[5-({1-[3-(1,1-difluoroethyl)[1,2,4]oxadiazol-5-yl]piperidin-4-yl}(2,2,2-trifluoroethyl)carbamoyl)pyrimidin-2-yl]-4-(2,5-difluorophenyl)pyrrolidin-3-yl}carbamic acid tert-butyl ester 
• 1376608-13-7 2-[(3R,4S)-3-amino-4-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrimidine-5-carboxylic acid [1-(3-isopropyl[1,2,4]oxadiazol-5-yl)piperidin-4-yl](methyl)amide 
• 1376610-96-6 [(3R,4S)-1-{5-[(1-carbamoylpiperidin-4-yl)(cyclopropyl)carbamoyl]pyrimidin-2-yl}-4-(2,5-difluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1376610-97-7 [(3R,4S)-1-{5-[(1-cyanopiperidin-4-yl)(cyclopropyl)carbamoyl]pyrimidin-2-yl}-4-(2,5-difluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1376610-99-9 [(3R,4S)-1-[5-(cyclopropyl-{1-[5-(1,1-difluoroethyl)[1,2,4]oxadiazol-3-yl]piperidin-4-yl}carbamoyl)pyrimidin-2-yl]-4-(2,5-difluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1376611-26-5 6-[(3R,4S)-3-tert-butoxycarbonylamino-4-(2,5-difluorophenyl)pyrrolidin-1-yl]nicotinic acid methyl ester 
• 1376611-29-8 6-[(3R,4S)-3-tert-butoxycarbonylamino-4-(2,5-difluorophenyl)pyrrolidin-1-yl]-5-cyanonicotinic acid methyl ester 
• 1376611-23-2 5-[(3R,4S)-3-tert-butoxycarbonylamino-4-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazine-2-carboxylic acid methyl ester 
• 1376611-06-1 [(3R,4S)-1-[5-({1[3-(1,1-difluoro-ethyl)-[1,2,4]oxadiazol-5-yl]-piperidin-4-yl}-methyl-sulfamoyl)-pyrimidin-2-yI]-4-(2,5-difluoro-phenyl)-pyrrolldin-3-yl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR1 19. Compounds having stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS

Therapeutic compounds are disclosed having the general formula (1) that are useful for the treatment of metabolic disorders, including type II diabetes.The compounds have activity as agonists of GPR1 19. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compotmds of the following formula (I) which have activity as agonists of GPR 119 and are useful for the treatment of metabolic disorders including type II diabetes.